Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial

被引：1

作者：

Khattak, Monica N. ^{[1
]}

Chichura, Anna M. ^{[1
]}

Lang, Julie E. ^{[1
]}

机构：

[1] Cleveland Clin Fdn, Div Breast Serv, Cleveland, OH 44195 USA

来源：

ANNALS OF SURGICAL ONCOLOGY | 2024年 / 31卷 / 03期

关键词：

D O I：

10.1245/s10434-023-14766-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This ASO perspective reviews the findings of a randomized, phase II clinical trial evaluating adjuvant trastuzumab emtansine (T-DM1) compared with paclitaxel and trastuzumab (TH) in stage I human epidermal growth factor receptor 2-positive breast cancer, as reported recently by the ATEMPT trial investigators. Patients treated with T-DM1 had better disease-free survival but did not have fewer treatment toxicities. The T-DM1-treated group had higher rates of treatment discontinuations, therefore long-term follow-up will be required to evaluate survival differences between T-DM1 and TH.

引用

页码：1423 / 1427

页数：5

共 23 条

[1] Trastuzumab emtansine: mechanisms of action and drug resistance
Barok, Mark
Joensuu, Heikki
Isola, Jorma
[J]. BREAST CANCER RESEARCH, 2014, 16 (02):
[2] Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
Barroso-Sousa, Romualdo
Tarantino, Paolo
Tayob, Nabihah
Dang, Chau
Yardley, Denise A.
Isakoff, Steven J.
Valero, Vicente
Faggen, Meredith
Mulvey, Therese
Bose, Ron
Hu, Jiani
Weckstein, Douglas
Wolff, Antonio C.
Reeder-Hayes, Katherine
Rugo, Hope S.
Ramaswamy, Bhuvaneswari
Zuckerman, Dan
Hart, Lowell
Gadi, Vijayakrishna K.
Constantine, Michael
Cheng, Kit
Briccetti, Frederick
Schneider, Bryan
Garrett, Audrey Merrill
Marcom, Kelly
Albain, Kathy
DeFusco, Patricia
Tung, Nadine
Ardman, Blair
Nanda, Rita
Jankowitz, Rachel C.
Rimawi, Mothaffar
Abramson, Vandana
Pohlmann, Paula R.
Van Poznak, Catherine
Forero-Torres, Andres
Liu, Minetta
Ruddy, Kathryn J.
Zheng, Yue
Rosenberg, Shoshana M.
Gelber, Richard D.
Trippa, Lorenzo
Barry, William
DeMeo, Michelle
Burstein, Harold
Partridge, Ann
Winer, Eric P.
Krop, Ian
Tolaney, Sara M.
[J]. NPJ BREAST CANCER, 2022, 8 (01)
[3] Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer
Bellon, Jennifer R.
Tayob, Nabihah
Yang, David D.
Tralins, Jordan
Dang, Chau T.
Isakoff, Steven J.
DeMeo, Michelle
Burstein, Harold J.
Partridge, Ann H.
Winer, Eric P.
Krop, Ian E.
Tolaney, Sara M.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 113 (01): : 117 - 124
[4] Magalhaes MAF, 2022, EINSTEIN-SAO PAULO, V20, DOI [10.31744/einstein_journal/2022gs6655, 10.31744/einstein_journal/2022GS6655]
[5] Differences in Breast Cancer Survival by Molecular Subtypes in the United States
Howlader, Nadia
Cronin, Kathleen A.
Kurian, Allison W.
Andridge, Rebecca
[J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2018, 27 (06) : 619 - 626
[6] Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Hudis, Clifford A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (01) : 39 - 51
[7] Mahtani Reshma, 2019, J Adv Pract Oncol, V10, P136
[8] NCCN, 2023, NCCN CLIN PRACTICE G
[9] Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer
Nowsheen S.
Viscuse P.V.
O’Sullivan C.C.
Sandhu N.P.
Haddad T.C.
Blaes A.
Klemp J.
Nhola L.
Herrmann J.
Ruddy K.J.
[J]. Current Breast Cancer Reports, 2017, 9 (3) : 173 - 182
[10] The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
Patel, Aena
Unni, Nisha
Peng, Yan
[J]. CANCERS, 2020, 12 (08) : 1 - 17

← 1 2 3 →